Clinical intelligence & editorial.

PubMed

Targeting Melasma: Innovations in Pigment Deposition and Photoaging in Cosmetic Dermatology.

ABSTRACT Background Melasma is a chronic, relapsing hyperpigmentation disorder driven by complex interactions among genetic predisposition, hormonal fluctuations, UV exposure, oxidative stress, inflammation, and photoaging. Its psychosocial impact is substantial, especially among women with darker skin types, and treatment remains challenging due to its multifactorial pathogenesis and high recurrence rates. Aims This review aims to synthesize current knowledge on melasma pathophysiology, hig...

Cosmetic Dermatology

Liao T, Luo R, Deng Y, Yang H, Du Y• January 1, 2026

PubMed

Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy.

Immunotherapy has reshaped the oncology landscape by enabling the immune system to recognize and eliminate malignant cells. Although immune checkpoint inhibitors (ICIs) targeting cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), programmed cell death‐1 (PD‐1), and programmed death‐ligand 1 (PD‐L1) have achieved durable responses in several cancers, their therapeutic benefit remains limited to a subset of patients, largely due to immune evasion, tumor heterogeneity, and immunosuppressive feat...

Cancer Immunotherapy

Bautista J, Echeverría CE, Maldonado-Noboa I, Adatty-Molina J, Suárez Urresta S, Coral-Riofrio EC, Araujo-Abad S, Kyriakidis NC, López-Cortés A• January 1, 2026

PubMed

Comparative analysis of second and third-generation nanobody-based CAR-NK cells targeting PSMA in prostate cancer immunotherapy: In silico and in vitro studies.

Objective(s): The use of CAR technology in the treatment of cancer cells is progressing, as well as the use of CAR T-cell in the treatment of blood malignancies is in the clinical trial stage. In this study, have compared the second and third generation CAR expressed in NK cells in dealing with prostate cancer cells. Materials and Methods: To optimize the CAR design for detection of NK-92 cells, an in silico approach to select between two tags (Flag and c-Myc tags) was initially employed, ult...

Cancer Immunotherapy

Gandomkar Ghalhar M, Karami Vandishi A, Ramazani A, Hajari Taheri F, Sharifzadeh Z, Abolhassani M, Soleimani M, Taghipour N, van Weerden WM, Bandehpour M, Hassani M, Bagherzadeh K• January 1, 2026

PubMed

Resveratrol as an immune checkpoint inhibitor to enhance the efficacy of breast cancer immunotherapy.

A major goal in cancer treatment is to convert “cold” tumors into “hot” ones by altering the tumor microenvironment (TME). Breast cancer is often a cold tumor and is resistant to immunotherapy. Resveratrol is a polyphenolic compound found in grapes, with antioxidant, anti-inflammatory, and potential cardioprotective and anti-aging properties. Resveratrol promotes the conversion of immunologically cold breast tumors into hot tumors, thereby increasing the efficacy of immunotherapy. This article r...

Cancer Immunotherapy

Alamolhodaei NS, Hudson BI, Mosaffa F, Boozari M• January 1, 2026

PubMed

Double Q-Learning for Intelligent Multi-Drug Scheduling in Cancer Chemotherapy Optimisation.

ABSTRACT Chemotherapy scheduling poses a challenging control problem due to the need to suppress tumour growth whilst maintaining systemic toxicity within clinically acceptable limits. This study develops a double Q‐learning–based controller for optimising daily dosing of a three‐drug regimen consisting of cisplatin, docetaxel and irinotecan. A pharmacokinetics–pharmacodynamics (PK/PD) tumour model with eight resistance states is used as the simulation environment. The controller aims to minimi...

Cancer Chemotherapy

Alizade B, Hajipour A• January 1, 2026

PubMed

Benign Growth, Malignant Protection? Insights into Benign Prostatic Hyperplasia and Prostate Cancer.

We read with great interest the recent review by Zarakowska et al [1] on the relationship between prostate cancer (PCa) and benign prostatic hyperplasia (BPH), which thoughtfully explores the roles of inflammation, oxidative stress, and epigenetics as common pathogenic links. The authors correctly highlight that chronic inflammation is a key factor in both conditions and cite epidemiological evidence suggesting that a diagnosis of BPH is associated with an increased risk of PCa incidence and mor...

Benign Prostatic Hyperplasia

Su PJ, Shao IH, Lin YH• January 1, 2026

PubMed

Is Oral Anticoagulation an Independent Predictor of Mortality in STEMI and High-Risk NSTEMI Patients After Primary PCI? A Propensity Score-Matched Retrospective Analysis.

Background Managing STEMI and high‐risk NSTEMI‐equivalent patients on chronic oral anticoagulation (OAC) undergoing primary PCI poses competing ischaemic and bleeding risks. Methods This single‐centre retrospective study enrolled 604 consecutive STEMI/high‐risk NSTEMI patients undergoing primary PCI (2012–2023). OAC users (n = 100) were compared with propensity score–matched controls (n = 203). Primary endpoints included all‐cause mortality, bleeding, stroke, recurrent MI and rehospitalisatio...

Anticoagulation

Polat R, Polat F, Velibey Y, Bolca O, İpek G• January 1, 2026

PubMed

International Brazilian Journal of Urology Congratulates the 2025 Best Reviewers.

In 2025 the International Brazilian Journal of Urology received the highest impact factor of his history (4.5) and this fact was possible because the serious peer review process of our Journal (1). In this year we received more than 600 papers. The peer review system is a very difficult process because is completely free. This process depends of the hard work of the experts in several topics reviewers by on the topic. The Editor-in-Chief would like to thanks all the reviewers and specially to th...

Urology

Favorito LA• November 1, 2025